Introduction
Patients with lupus nephritis (LN) may experience frequent flares over the course of their disease. 1 Clinical and laboratory features are often not sufficient to guide the treatment of these patients, hence the need for repeat renal biopsies. [2] [3] [4] As there is no consensus about repeat renal biopsies in patients with LN, they are either performed as protocol biopsies at the end of induction or maintenance treatment or only when a flare is suspected; but this is centre specific. 5, 6 LN patients with chronic renal scarring may continue to have low-grade proteinuria even without any disease activity in their kidneys, resulting in unnecessary immunosuppression with potential for complications. 7 Alvarado et al., in a study of 25 LN patients in Argentina, illustrated this well when they found that 60% of those with ongoing proteinuria did not have any activity in their kidneys at the repeat biopsy. 7 Thus, clinically quiescent LN during ongoing maintenance treatment presents a challenge regarding timing of reduction or discontinuation of immunosuppression without repeating a renal biopsy as there may be histologically active disease. 7, 8 One of the important reasons for repeat biopsies in patients with LN is to identify significant class transformations requiring change of therapy. 2, [9] [10] [11] [12] [13] [14] [15] However, there are questions regarding the value of these repeat biopsies if the first biopsy showed proliferative LN given that the same is likely to be seen on repeat biopsy. 15, 16 In one study, 84% of patients with proliferative histology in their reference biopsy remained in a proliferative class of LN at repeat biopsy. 17 Currently, there is insufficient evidence for major guidelines to make strong recommendations on repeat renal biopsy. 18 At our centre in Cape Town, repeat renal biopsies are performed in patients with LN to assess disease activity during a flare or to determine degree of chronic changes; both criteria driven by the need to understand if treatment change will be required.
The utility of a repeat renal biopsy in patients with biopsy proven LN has not been thoroughly investigated in Africa. The aim of this study is therefore to assess the clinical relevance of repeat renal biopsy in patients with LN at a single centre.
Methods
This study was approved by the Human Research Ethics Committee of the University of Cape Town (HREC Ref 732/2014) and was designed as a retrospective analysis of repeat renal biopsies performed for patients with known LN from 1 January 2003 to 31 December 2014. We identified eligible patients through our local renal biopsy database. Patients who have had only one renal biopsy, patients with transplant biopsies and all other cases of non-lupus biopsies were excluded. Although a few patients had more than two biopsies performed during the period of assessment, our focus was to compare the clinical, biochemical, histological and treatment features observed between first and second biopsies. Paper and electronic records were searched to obtain relevant demographic, clinical, histological and treatment information on all patients who were included. The indication for repeat renal biopsy was categorized as: (i) active urinary sediment, (ii) elevated serum creatinine, (iii) elevated serum creatinine with a urinary abnormality (active sediment, red cells present, proteinuria), and (iv) elevated proteinuria. The histology from all the biopsies was reviewed by the same pathologist and reported using the International Society of Nephrology and Renal Pathology Society (ISN/ RPS) class of LN. 19 Activity and chronicity scores for each patient at the time of first and second biopsies were assessed and recorded using standard criteria. 20 The average time between first and second biopsies was calculated and recorded. Clinical features, histological findings and differences in frequency of LN class between biopsies were recorded. The estimated glomerular filtration rate (eGFR) was calculated using the Modification of Diet in Renal Disease (MDRD) equation. 21 Treatment received for induction and maintenance therapies at first and second renal biopsies were also documented. Changes to treatment that occurred due to the histologic findings of the second renal biopsy were recorded as: (i) treatment escalation -if there was need to increase dose of corticosteroids or other alkylating agents or introduce a new immunosuppression; (ii) treatment reduction -if there was need to stop or reduce the dose of ongoing immunosuppression; and (iii) no change to treatment if there was no change in dose or type of immunosuppression given after the repeat biopsy.
Statistical analysis
The data were analyzed using SPSS Version 23.0 for Windows (SPSS Chicago, IL). The results were presented as percentages or as mean AE SD. The student's t-test (for continuous variables) and the chi-squared test (for categorical variables) were used to test for differences between variables at the first and second biopsies. p-values less than 0.05 were considered statistically significant.
Results
A total of 2581 native renal biopsies were performed during the study period. Of these, 369 (14.3%) were in patients with LN, of which 44 patients (11.9%) had at least one repeat biopsy. The baseline and demographic characteristics of the patients at biopsy 1 and 2 are shown in Table 1 . The average age at first biopsy was 25.7 AE 10.3 years and 28.4 AE 10.2 years at second biopsy with the mean biopsy interval being 2.8 AE 1.8 years. Most patients were females (81.8%) and there was a predominance of patients of mixed ancestry (75%), while black Africans and white patients made up 22.7% and 1.8%, respectively.
Elevated proteinuria was the main indication for renal biopsy at first and second biopsy (48.7% vs 36.1%; p ¼ 0.489). A significantly increased number of patients had a repeat biopsy due to elevated serum creatinine, compared to the first biopsy (5.1% vs 13.9%; p ¼ 0.016). Similarly, there was an increase in the proportion of patients who had a re-biopsy due to elevated serum creatinine with abnormal urine sediment at second biopsy than at first biopsy (12.8% vs 27.8%, p ¼ 0.895) ( Table 1) .
There was a significant reduction in the proportion of patients with positive double stranded DNA at second biopsy (65.9% vs 63.6%; p ¼ 0.022) as shown in the Table. There was also significant worsening of eGFR between first and second biopsies (88.9 AE 49.2 ml/min vs 54.7 AE 59.0 ml/min; p ¼ 0.001) as well as significant worsening of proteinuria (3.0 g/24 h AE 3.0 vs 5.0 g/24 h AE 3.9, p ¼ 0.019) ( Figure 1 ).
The mean number of glomeruli obtained at both biopsies was similar (14.1 AE 8.7 and 14.3 AE 7.5; p ¼ 0.890) and there were no significant differences in the average number of cellular crescents
number of fibrous crescents (p ¼ 0.173) and percentage of interstitial fibrosis (p ¼ 0.309) seen. However, there were significantly more patients with crescents at the second biopsy (p ¼ 0.005). The mean activity index (3.9 AE 4.4 vs 7.0 AE 5.7; p ¼ 0.005), chronicity index (1.0 AE 1.5 vs 3.5 AE 2.7; p < 0.000) and number of sclerosed glomeruli (0.5 AE 1.2 vs 4.3 AE 7.8; p ¼ 0.004) were significantly raised at the repeat biopsy time point. In addition, we frequently observed transformation in histological class between initial and follow-up biopsies; 40.9% had proliferative LN at first biopsy compared to 70.4% at second biopsy (Figure 2 ). At second biopsy, class transformation was 100% for patients with class I LN at first biopsy, 80% for those with class II LN, and 86% for those with class V LN ( Table 2 ). Most of the transformation of class at second biopsy was to class IV. The majority of patients with proliferative LN at first biopsy (77.8%) remained in one of the proliferative classes, whereas 65.4% with an initial non-proliferative LN class transformed into a proliferative class at second biopsy. Treatment given for induction and maintenance therapies as well as other adjunctive therapies given to patients after the first and second biopsies are shown in Table 3 . The repeat biopsy resulted in immunosuppressive treatment escalation in 72.5%, reduction in 12.5% and no changes to treatment in 15.0%. Hence, there was an overall treatment change in 85.0% as a result of the second biopsy (Table 3 ).
Discussion
This study shows that there is a significant class transformation in patients with LN undergoing a repeat renal biopsy at our centre. The observed change in LN class between the initial and followup biopsies led to significant change in treatment following repeat biopsy. This therefore points to the need for protocols for repeat biopsies in our setting given the implications for disease outcome. 
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One large international cohort study of repeat biopsy in patients with LN also found significant class switch at repeat biopsy and concluded that a repeat biopsy strategy could provide additional information on long-term renal outcomes. 22 The same study also suggested that a strategy of protocol biopsies could be useful in clinical trials to better understand the therapeutic response and the natural history of LN. 22 Although the Kidney Disease: Improving Global Outcomes (KDIGO) guideline does not specifically provide information regarding the timing of a repeat biopsy in patients with LN, repeat biopsies have often been performed during a disease flare 10, 12, 13, 17 or as protocol biopsies at the end of induction therapy 7, [23] [24] [25] or after one to two years to assess the efficacy of maintenance therapy. 6, 15, 26, 27 In a study comparing the histologic and clinical responses of proliferative LN to standard-of-care induction therapies, Malvar et al. found that seven patients showed persistent cellular crescents and sub endothelial immune deposits and/or glomerular capillary necrosis at repeat biopsy and that two of these patients had achieved complete clinical renal response, one patient had a partial renal response and four had no renal response. 25 The patients were treated for another six months with mycophenolate mofetil (3 g/day), before being placed on maintenance immunosuppression. They concluded that early clinical and histologic outcomes are discordant in proliferative LN, and neither correlates with long-term renal outcome. 25 However, use of protocol biopsies, rather than biopsies performed only during a clinical disease flare, may be more likely to provide better evidence Table 4 Features from selected studies of repeat renal biopsies in patients with lupus nephritis from various centres Pagni et al. 22 Daleboudt et al. 17 Wang et al. 9 Greloni et al. 12 Alvarado et al. 7 Lu et al. 30 Esdaile et al. 15 Bajaj et al. 10 Current study for disease progression, patient outcome and need for early treatment change. More data is still needed from prospective studies and clinical trials to define the role of protocol biopsies in understanding disease pathogenesis and outcomes.
Country
Our study also showed that most patients who on initial biopsy had a proliferative LN, especially patients with class IV LN, often remained in the same class at follow-up biopsy. This is in agreement with Daleboudt et al. who have reported that 84% of patients in their study with proliferative LN at first biopsy continued to have proliferative disease at repeat biopsy. 17 This finding questions the value of repeating a kidney biopsy in such patients if the initial biopsy was of a proliferative type. On the contrary, some may justify the need for repeat biopsies in patients with initial proliferative LN given that it often leads to change in current treatment. 12 However, the change of treatment, as reported in this study, is that of change from ongoing maintenance treatment (minimal immunosuppression) to a new induction phase treatment (increased dose or new immunosuppression) ( Table 3 ). As shown in Table 3 , the proportion of patients getting induction treatment after second biopsy appears fewer than at first biopsy because the change in treatment is from maintenance treatment before second biopsy not comparison between induction therapies at the two biopsies. Thus, whether a repeat biopsy in patients with initial proliferative LN is only needed to guide therapeutic changes will remain a matter of debate. This is because, in many patients, treatment escalation would still have occurred from a clinical perspective due to an ongoing flare.
Change in chronicity score at repeat biopsy may remain a strong reason to advocate for repeat biopsy in patients with LN and needs to be reported in all biopsies of patients with LN. 28 In the current study, there was a significant increase in both activity and chronicity indices between biopsies ( Figure 3 ), translating to significantly reduced eGFR and increased 24-hour proteinuria between biopsies (Figure 1) . Several other studies have shown significant increases in chronicity scores at repeat biopsy, even after initial successful treatment. 27, 29 Bao et al. reported a significantly ameliorated activity index (p < 0.0001) at repeat biopsy, whereas chronicity index had significantly increased (p ¼ 0.028) in patients at complete remission after induction therapy in a study that investigated the value of multi-targeted therapy in patients with proliferative LN. 29 They found no difference in activity index (p ¼ 0.346) and significant increase in chronicity index (p ¼ 0.032) for patients who did not achieve complete remission after induction therapy. 29 The average biopsy interval in many studies that report increased chronicity score at repeat biopsy is often between 2.1 to 6 years (Table 4) . 7, 9, 12, 17, 22, 24, 30 The average biopsy interval from our centre was 2.8 AE 1.8 years, which could be the reason for the significantly increased chronicity score obtained at repeat biopsy.
There are some limitations we encountered in conducting this research; for instance, although the pathologists at our centre use the ISN/RPS classification for LN, subclasses that report segmental or global lesions in the biopsy are not routinely reported. Such information may have helped us to understand how those patients with a predominantly proliferative class of disease changed classes (e.g. from IV[S] to IV[G]) even though they still remained within the proliferative type of LN. Other limitations are the retrospective design of the study and the low sample size available for analysis. However, the strength of this study is that it has been reported from a developing country setting where renal biopsies are usually not available in the evaluation of patients and therefore may provide assurance for the clinical treatment of patients with suspected proliferative disease in the absence of facilities to perform a kidney biopsy. We, however, urge that a biopsy be considered to guide therapy in such patients where possible.
Conclusion
Repeat renal biopsies in patients with LN presents a useful means of assessing disease progression and provides guidance regarding modification of treatment.
